ReviewClinica chimica acta; international journal of clinical chemistry2007
The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.
Review in Clinica chimica acta; international journal of clinical chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Bactericidal/permeability increasing protein gene polymorphism and inflammatory bowel diseases: meta-analysis of five case-control studies.International journal of colorectal disease · 2017Pooled it
- Article
- Microscopic Polyangiitis After Pulmonary Nontuberculous Mycobacterial Disease: A Case Report and Literature Review.Respirology case reports · 2026Article
- Characterizing the impact of intracutaneous dissemination on host responses duringFrontiers in immunology · 2026Article
- Bactericidal Permeability-Increasing Protein (BPI) InhibitsBiomolecules · 2024Article
- Salivary bactericidal/permeability-increasing protein: A novel inflammatory marker associated with periodontitis.Clinical oral investigations · 2023Article
- Identification and Functional Analysis ofGenes · 2023Article
- Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators.International journal of molecular sciences · 2023Review
- Human neutrophilsImmunological reviews · 2023Review
- Cystic fibrosis autoantibody signatures associate withFrontiers in immunology · 2023Article
- Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram.Clinical rheumatology · 2022Article
- Bactericidal/Permeability-Increasing Protein Downregulates the Inflammatory Response in In Vivo Models of Arthritis.International journal of molecular sciences · 2022Article
- BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus.Theranostics · 2021Article
- Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.Journal of translational autoimmunity · 2021Review
- Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs).Frontiers in microbiology · 2021Review
- Gene Expression in Embryos From Norwegian Red Bulls With High or Low Non Return Rate: An RNA-Seq Study of in vivo-Produced Single Embryos.Frontiers in genetics · 2021Article
- IgA autoantibodies directed against self DNA are elevated in cystic fibrosis and associated with more severe lung dysfunction.Autoimmunity · 2020Article
- Microbial gas vesicles as nanotechnology tools: exploiting intracellular organelles for translational utility in biotechnology, medicine and the environment.Microbiology (Reading, England) · 2020Review
- Sex Differences in the Blood Transcriptome Identify Robust Changes in Immune Cell Proportions with Aging and Influenza Infection.Cell reports · 2019Article
- Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization.Journal of clinical laboratory analysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Gram-negative bacteria (GNB) and their endotoxin present a constant environmental challenge. Endotoxins can potently signal mobilization of host defenses against invading GNB but also potentially induce severe pathophysiology, necessitating controlled initiation and resolution of endotoxin-induced inflammation to maintain host integrity. The bactericidal/permeability-increasing protein (BPI) is a pluripotent protein expressed, in humans, mainly neutrophils. BPI exhibits strong antimicrobial activity against GNB and potent endotoxin-neutralizing activity. BPI mobilized with neutrophils in response to invading GNB can promote intracellular and extracellular bacterial killing, endotoxin neutralization and clearance, and delivery of GNB outer membrane antigens to dendritic cells. Tissue expression by dermal fibroblasts and epithelia could further amplify local levels of BPI and local interaction with GNB and endotoxin, helping to constrain local tissue infection and inflammation and prevent systemic infection and systemic inflammation. This review article focuses on the structural and functional properties of BPI with respect to its contribution to host defense during GNB infections and endotoxin-induced inflammation and the genesis of autoantibodies against BPI that can blunt BPI activity and potentially contribute to chronic inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.